Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity

Internal Medicine Journal

Volumn 37, Issue 1, 2007, Pages 55-59

  Lim, A K H ^a   Donnan, G ^a   Chambers, B ^a   Ierino, F L ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

Cyclosporine; Myasthenia gravis; Mycophenolate mofetil; Nephrotoxicity

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CREATININE; CYCLOSPORIN A; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PREDNISOLONE; PYRIDOSTIGMINE; STEROID; TELMISARTAN;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CUSHINGOID SYNDROME; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MALE; MOOD DISORDER; MYASTHENIA GRAVIS; NEPHROTOXICITY; OSTEOPENIA; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADULT; CYCLOSPORINE; DIABETIC NEPHROPATHIES; DRUG EVALUATION; FEMALE; HUMANS; HYPERTENSION, RENAL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID; PLASMA EXCHANGE; PREDNISOLONE; RECURRENCE; THYMECTOMY;

EID: 33845515282     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01222.x     Document Type: Article

References (16)

1. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporine nephrotoxicity. J Am Soc Nephrol 1990; 1: 162-79.
2. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-46.
3. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-40.
4. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384-9.
5. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55: 448-50.
6. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997; 244: 542-7.
7. Tindall RS, Phillips JT, Rollins JA, Well L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 539-51.
8. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998; 51: 912-13.
9. Meriggioli MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000; 23: 1287-9.
10. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001; 46: 79-82.
11. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56: 94-6.
12. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61: 1438-40.
13. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001; 56: 97-9.
14. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot trial. Ann N Y Acad Sci 2003; 998: 494-9.
15. Meriggioli MN, Rowin J. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol 2003; 20: 382-5.
16. Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998; 65: 661-7.